New vaccine aims to shield kids from 24 pneumococcal strains

NCT ID NCT06675032

Ongoing ⭐️ VACCINE ⭐️ Sponsor: Shanghai Reinovax Biologics Co.,LTD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new vaccine called PCV24, designed to protect children against 24 types of pneumococcal bacteria. The study involves 230 healthy children aged 6 weeks to 17 years and will check for side effects and measure immune response. The vaccine is given as an injection, with the number of doses depending on the child's age.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 24-valent pneumococcal polysaccharide conjugate vaccine (PCV24)
What this could lead to: If successful, this could lead to a vaccine that protects children against 24 types of pneumococcal bacteria, potentially preventing serious infections like pneumonia and meningitis.
What could go wrong: This is an early Phase 1 trial with only 230 participants, so safety and immune response are still being tested. The vaccine may not work as expected or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL INFECTIOUS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PNEUMOCOCCAL INFECTIOUS DISEASE

Contacts and locations

Show contact details

Locations

Luzhou District Center for Disease Control and Prevention, Changzhi City

Changzhi, Shanxi, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.